...
首页> 外文期刊>Thoracic cancer. >Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case
【24h】

Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case

机译:对吉非替尼有反应的臂状软组织转移的肺鳞状细胞癌:一例罕见病例的报告

获取原文

摘要

Metastasis of lung cancer to soft tissue is rare and patient outcomes are generally poor. There are no reports describing soft tissue metastasis in lung squamous cell carcinoma (SCC), in which gefitinib treatment was effective not only for the primary tumor but also the metastatic lesion. A 61-year-old Asian woman presented to our facility with pain and a mass in the brachium. An additional tumor was identified in the lung. As we suspected soft tissue metastasis of lung cancer, an incisional biopsy was performed, yielding a diagnosis of SCC. The brachial tumor continued to grow and became exposed at the biopsy site when the incisional wound dehisced. Because the biopsied specimen was positive for an epidermal growth factor receptor (EGFR) gene mutation, we commenced gefitinib administration. This treatment resulted in the rapid shrinkage of both the brachial metastasis and the primary tumor, followed by healing of the wound. Therefore, tyrosine kinase inhibitors should be used for cases that present EGFR activating mutations independently from the presence of skin and soft tissue metastases.
机译:肺癌转移至软组织的情况很少,患者预后通常较差。没有报道描述肺鳞状细胞癌(SCC)的软组织转移,其中吉非替尼治疗不仅对原发肿瘤有效,而且对转移性病变也有效。一名61岁的亚裔妇女在我们的设施内出现疼痛和大包块。在肺中发现了另外的肿瘤。由于我们怀疑肺癌的软组织转移,因此进行了切开活检,诊断为SCC。当切开伤口开裂时,肱骨肿瘤继续生长并暴露于活检部位。由于活检标本对表皮生长因子受体(EGFR)基因突变呈阳性,因此我们开始服用吉非替尼。该治疗导致肱转移和原发性肿瘤迅速缩小,然后伤口愈合。因此,酪氨酸激酶抑制剂应用于独立于皮肤和软组织转移的存在而出现EGFR激活突变的病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号